Cargando…

Angiotensin receptor blockers in heart failure after the ELITE II trial

Specific blockers of the angiotensin type1 receptor, angiotensin receptor blockers (ARBs), have been introduced as an alternative to angiotensin-converting enzyme inhibitors (ACEi) for the treatment of heart failure. In comparison with ACEi, ARBs are better tolerated and have similar effects on haem...

Descripción completa

Detalles Bibliográficos
Autor principal:	Willenheimer, Ronnie
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59604/ https://www.ncbi.nlm.nih.gov/pubmed/11714415 http://dx.doi.org/10.1186/cvm-1-2-079

Ejemplares similares

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19
por: Khalili, Azadeh, et al.
Publicado: (2021)

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure
por: Sohani, Zahra N., et al.
Publicado: (2023)

Preventive Effects of the Angiotensin-II Receptor Blocker on Atrial Remodeling in an Ischemic Heart Failure Model of Rats
por: Yoon, Namsik, et al.
Publicado: (2013)

Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence
por: Hennessy, Sean, et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials
por: Tai, Chenhui, et al.
Publicado: (2017)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Sudden death prevention in heart failure: The case of CIBIS III
por: VANOLI, EMILIO, et al.
Publicado: (2006)

Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis
por: Wang, Zexu, et al.
Publicado: (2023)

Synergistic effects of HMG‐CoA reductase inhibitor and angiotensin II receptor blocker on load‐induced heart failure
por: Ito, Yusuke, et al.
Publicado: (2018)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Association between prognosis and the use of angiotensin‐converting enzyme inhibitors and/or angiotensin II receptor blockers in frail patients with heart failure with preserved ejection fraction
por: Sunaga, Akihiro, et al.
Publicado: (2022)

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
por: Baumhäkel, Magnus, et al.
Publicado: (2011)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure
por: YOON, NAMSIK, et al.
Publicado: (2013)

Renin-angiotensin-aldosterone system and kidney interactions in heart failure
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker
por: Forsdyke, Donald R
Publicado: (2015)

What is the association of acute renal failure, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in a young patient?
por: Yüksel, Selçuk, et al.
Publicado: (2013)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
por: Kim, Jihoon, et al.
Publicado: (2023)

Prognostic Impacts of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome Patients Without Heart Failure
por: Chen, Runzhen, et al.
Publicado: (2022)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease – Demystifying controversies
por: Muneer, Kader, et al.
Publicado: (2017)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin II receptor blockers induce autophagy in prostate cancer cells
por: Woo, Yunseo, et al.
Publicado: (2017)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials
por: Zhao, Yun-Tao, et al.
Publicado: (2016)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
por: Matsumura, Yoshihisa, et al.
Publicado: (2015)

Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction
por: Gilstrap, Lauren G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_888dsp0b1o73dntnj9gkmj7afq